Stockreport

Passage Bio Reports Third Quarter 2025 Financial Results and Provides Recent Business Highlights

Passage Bio, Inc.  (PASG) 
PDF Actively enrolling Cohort 3 (FTD-GRN) and Cohort 4 (FTD-C9orf72) patients in ongoing upliFT-D study Aligned with the U.S. Food and Drug Administration (FDA) on an a [Read more]